Mereo BioPharma Shareholder Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MREO?
Source: Globenewswire
- Lawsuit Background: Shareholders of Mereo BioPharma Group plc who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Mereo provided overly positive statements regarding the Phase 3 ORBIT and COSMIC programs while concealing the fact that neither study achieved its primary endpoints, misleading investors and impacting their decisions.
- Stock Price Plummet: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's stock price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Shareholder Action Steps: Shareholders must register for the class action by April 6, 2026, to participate, and upon registration, they will receive status updates throughout the case lifecycle, reflecting the company's commitment to shareholder rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.361
Low
0.50
Averages
2.08
High
5.00
Current: 0.361
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mereo BioPharma Shareholder Class Action Notice
- Lawsuit Background: Shareholders of Mereo BioPharma Group plc who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Mereo provided overly positive statements regarding the Phase 3 ORBIT and COSMIC programs while concealing the fact that neither study achieved its primary endpoints, misleading investors and impacting their decisions.
- Stock Price Plummet: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's stock price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Shareholder Action Steps: Shareholders must register for the class action by April 6, 2026, to participate, and upon registration, they will receive status updates throughout the case lifecycle, reflecting the company's commitment to shareholder rights.
See More
Mereo BioPharma Reports $41.9 Million FY Net Loss
- Financial Performance: Mereo BioPharma reported a net loss of $41.9 million for FY 2025, indicating high expenditures in R&D and operations that could impact future financing capabilities.
- Revenue Situation: The company generated only $500,000 in revenue during the same fiscal year, significantly below industry expectations, reflecting insufficient market acceptance of its products and potentially eroding investor confidence.
- Cash Flow Status: As of December 31, 2025, Mereo had cash and cash equivalents of $41.0 million, providing some liquidity; however, without significant revenue growth, the company may face cash flow pressures.
- Market Reaction: Mereo BioPharma's presentation at the J.P. Morgan Healthcare Conference failed to boost its stock price, indicating market concerns about its future prospects, which could hinder financing and partnership opportunities.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to ensure investor rights are protected.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, necessitating careful consideration of their next steps.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
Mereo BioPharma Faces Securities Class Action Over BMD Claims
- Lawsuit Background: Mereo BioPharma Group plc is facing a securities class action for allegedly misrepresenting the relationship between bone mineral density (BMD) improvements and fracture reduction, with a court deadline of April 6, 2026, for lead plaintiff applications, highlighting a strong demand for transparency from investors.
- Management Accountability: The lawsuit claims that management failed to disclose the lack of control group comparisons in Phase 2 data while touting a 67% reduction in annualized fracture rates, which could undermine investor confidence due to insufficient evidence of causation.
- Industry Impact: This case underscores the fundamental question of whether BMD improvements can serve as a reliable surrogate endpoint for fracture reduction; while the company has achieved some progress in BMD, it has not met market expectations for clinically meaningful fracture reductions, potentially affecting future financing and market performance.
- Legal Support: Levi & Korsinsky, LLP, recognized as a leader in shareholder rights litigation, has been ranked in ISS Securities Class Action Services' Top 50 for seven consecutive years, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Mereo BioPharma Shareholder Class Action Notice
- Lawsuit Background: Shareholders of Mereo BioPharma Group plc who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Mereo provided overly positive statements regarding the Phase 3 ORBIT and COSMIC programs while concealing the fact that neither study achieved its primary endpoints, misleading investors and impacting their decisions.
- Stock Price Plummet: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's stock price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Shareholder Action Steps: Shareholders must register for the class action by April 6, 2026, to participate, and upon registration, they will receive status updates throughout the case lifecycle, reflecting the company's commitment to shareholder rights.
See More
Mereo BioPharma Reports $41.9 Million FY Net Loss
- Financial Performance: Mereo BioPharma reported a net loss of $41.9 million for FY 2025, indicating high expenditures in R&D and operations that could impact future financing capabilities.
- Revenue Situation: The company generated only $500,000 in revenue during the same fiscal year, significantly below industry expectations, reflecting insufficient market acceptance of its products and potentially eroding investor confidence.
- Cash Flow Status: As of December 31, 2025, Mereo had cash and cash equivalents of $41.0 million, providing some liquidity; however, without significant revenue growth, the company may face cash flow pressures.
- Market Reaction: Mereo BioPharma's presentation at the J.P. Morgan Healthcare Conference failed to boost its stock price, indicating market concerns about its future prospects, which could hinder financing and partnership opportunities.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to ensure investor rights are protected.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, necessitating careful consideration of their next steps.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Mereo BioPharma, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal liabilities for the company.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by April 6, 2026, or risk losing the opportunity for potential recovery, highlighting the urgency of legal proceedings.
- Stock Price Plunge Impact: Mereo BioPharma announced on December 29, 2025, that two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting market pessimism about the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages all investors and whistleblowers related to Mereo BioPharma to reach out for more information to protect investor rights, emphasizing the importance of legal support.
See More
Mereo BioPharma Faces Securities Class Action Over BMD Claims
- Lawsuit Background: Mereo BioPharma Group plc is facing a securities class action for allegedly misrepresenting the relationship between bone mineral density (BMD) improvements and fracture reduction, with a court deadline of April 6, 2026, for lead plaintiff applications, highlighting a strong demand for transparency from investors.
- Management Accountability: The lawsuit claims that management failed to disclose the lack of control group comparisons in Phase 2 data while touting a 67% reduction in annualized fracture rates, which could undermine investor confidence due to insufficient evidence of causation.
- Industry Impact: This case underscores the fundamental question of whether BMD improvements can serve as a reliable surrogate endpoint for fracture reduction; while the company has achieved some progress in BMD, it has not met market expectations for clinically meaningful fracture reductions, potentially affecting future financing and market performance.
- Legal Support: Levi & Korsinsky, LLP, recognized as a leader in shareholder rights litigation, has been ranked in ISS Securities Class Action Services' Top 50 for seven consecutive years, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
